20197-87-9

Basic information

• Product Name: 2,6-DICHLOROQUINAZOLIN-4(3H)-ONE
• Synonyms: 2,6-DICHLOROQUINAZOLIN-4(3H)-ONE;2,6-dichloroquinazolin-4-ol;2,6-dichloro-3,4-dihydroquinazolin-4-one;2,6-DICHLOROQUIZOLIN-4(3H)-ONE;2,6-dichloro-1H-quinazolin-4-one
• CAS NO: 20197-87-9
• Molecular Formula: C₈H₄Cl₂N₂O
• Molecular Weight: 215.04
• Mol File: 20197-87-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 260 °C at 760 mmHg
• Flash Point: 111 °C
• Appearance: /
• Density: 1.625 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,6-DICHLOROQUINAZOLIN-4(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLOROQUINAZOLIN-4(3H)-ONE(20197-87-9)
• EPA Substance Registry System: 2,6-DICHLOROQUINAZOLIN-4(3H)-ONE(20197-87-9)

Safety Data

• Hazardous Substances Data: 20197-87-9(Hazardous Substances Data)

Usage

General Description

2,6-dichloroquinazolin-4(3H)-one is a chemical compound with the molecular formula C8H4Cl2N2O. It is a white to light yellow crystalline powder that is sparingly soluble in water. 2,6-dichloroquinazolin-4(3H)-one has a wide range of applications, including its use as a precursor in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of various organic compounds. Additionally, 2,6-dichloroquinazolin-4(3H)-one has been studied for its potential biological activities, including its role as a potential antimicrobial agent. Overall, this chemical compound is an important building block in the field of organic synthesis and has diverse potential applications in the pharmaceutical and agricultural industries.

InChI:InChI=1S/C8H4Cl2N2O/c9-4-1-2-6-5(3-4)7(13)12-8(10)11-6/h1-3H,(H,11,12,13)

Upstream product

• 20028-68-6 2,4,6-trichloroquinazoline 
• 1640-60-4 6-chloro-1,2,3,4-tetrahydroquinazoline-2,4-dione 
• 635-21-2 5-chloroanthranilic acid 

Downstream Products

• 769158-24-9 2-((2,6-dichloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 33017-92-4 6-chloro-2-(4-methylpiperazin-1-yl)quinazolin-4(3H)-one 
• 105150-90-1 6-Chloro-2-[3-(3-piperidin-1-ylmethyl-phenoxy)-propylamino]-3H-quinazolin-4-one 

Relevant articles and documents

PIPERAZINE DERIVATIVES AS MAGL INHIBITORS

The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design to Minimize Host Kinase Interactions

Drug resistant tuberculosis (TB) infections are on the rise and antibiotics that inhibit Mycobacterium tuberculosis through a novel mechanism could be an important component of evolving TB therapy. Protein kinase A (PknA) and protein kinase B (PknB) are both essential serine-threonine kinases in M. tuberculosis. Given the extensive knowledge base in kinase inhibition, these enzymes present an interesting opportunity for antimycobacterial drug discovery. This study focused on targeting both PknA and PknB while improving the selectivity window over related mammalian kinases. Compounds achieved potent inhibition (Ki ≈ 5 nM) of both PknA and PknB. A binding pocket unique to mycobacterial kinases was identified. Substitutions that filled this pocket resulted in a 100-fold differential against a broad selection of mammalian kinases. Reducing lipophilicity improved antimycobacterial activity with the most potent compounds achieving minimum inhibitory concentrations ranging from 3 to 5 μM (1-2 μg/mL) against the H37Ra isolate of M. tuberculosis.

Substituted piperazine compounds, application method and applications thereof

The invention discloses substituted piperazine compounds, an application method and applications thereof. Specifically, the invention relates to piperazine compounds and pharmaceutical compositions thereof for inhibiting reuptake of 5-hydroxytryptamine and/or stimulation of 5-HT1A acceptor. The invention also relates to a preparation method of the compounds and pharmaceutical compositions thereof, and an application of the compounds and pharmaceutical compositions thereof in the treatment of central nervous system dysfunction.